Chenlu Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chenlu Li has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chong Huang
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, School of Stomatology, The Fourth Military Medical University, Xi’an 710032, China
4 shared publications - Chunlin Zong
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, School of Stomatology, The Fourth Military Medical University, Xi’an 710032, China
4 shared publications - Dandan Wang
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, School of Stomatology, The Fourth Military Medical University, Xi’an 710032, China
4 shared publications - Heng Li
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, School of Stomatology, The Fourth Military Medical University, Xi’an 710032, China
4 shared publications - Lei Tian
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, School of Stomatology, The Fourth Military Medical University, Xi’an 710032, China
4 shared publications - Ting Mou
State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, National Clinical Research Center for Oral Diseases, Shaanxi Clinical Research Center for Oral Diseases, Department of Oral and Maxillofacial Surgery, School of Stomatology, The Fourth Military Medical University, Xi’an 710032, China
4 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 623
Correction: Li et al. Multifunctional Fe3O4@ZIF-8 Nanoparticles with Antibiosis and Osteogenesis for Treatment of Jaw Osteomyelitis. Pharmaceutics 2026, 18, 359
- 20 May 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (5) , 623
Open AccessCorrection: Li et al. Multifunctional Fe3O4@ZIF-8 Nanoparticles with Antibiosis and Osteogenesis for Treatment of Jaw Osteomyelitis. Pharmaceutics 2026, 18, 359
- Open Access
- 13 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 359
Multifunctional Fe3O4@ZIF-8 Nanoparticles with Antibiosis and Osteogenesis for Treatment of Jaw Osteomyelitis
Background/Objectives: Jaw osteomyelitis (OM) is a refractory purulent inflammation caused by bacterial infection, characterized by persistent infection, excessive bone resorption, and resultant bone defects. Currently, mainstream therapies for jaw OM struggle to eradicate persistent infections, avoid antibiotic resistance, and repair infected bone defects, posing a critical challenge in clinical practice. Methods: Herein, the Fe3O4@ZIF-8 core–shell nanoparticles (NPs) platform designed for jaw OM treatment consisted of Fe3O4 as the core and zeolitic imidazolate framework-8 (ZIF-8) as the shell. Results: The core–shell platform not only integrated the pH-responsive degradation capability of ZIF-8 but also retained the superparamagnetism of Fe3O4 NPs. In the acidic, infectious microenvironment, Fe3O4@ZIF-8 NPs underwent continuous degradation, releasing Zn2+, thereby conferring potent antibacterial activity. The specific antibacterial mechanism of the nanoparticles lies in the fact that high concentrations of Zn2+ directly disrupted bacterial cell membranes and inhibited the bacterial heat shock response. This dysregulates bacterial proteostasis, rendering the bacteria more sensitive to external adverse stresses, ultimately leading to bacterial death. With ZIF-8 framework degradation, the encapsulated Fe3O4 NPs were released. Under static magnetic field (SMF) synergy, Fe3O4 NPs collaborated with Zn2+ to promote bone regeneration and repair infected bone defects in jaw OM lesions. Conclusions: As a multifunctional core–shell platform, Fe3O4@ZIF-8 NPs meet the dual clinical needs of antibiosis and osteogenesis, offering a promising translational strategy for jaw OM therapy.
- 13 March 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 359
Open AccessMultifunctional Fe3O4@ZIF-8 Nanoparticles with Antibiosis and Osteogenesis for Treatment of Jaw Osteomyelitis
Background/Objectives: Jaw osteomyelitis (OM) is a refractory purulent inflammation caused by bacterial infection, characterized by persistent infection, excessive bone resorption, and resultant bone defects. Currently, mainstream therapies for jaw OM struggle to eradicate persistent infections, avoid antibiotic resistance, and repair infected bone defects, posing a critical challenge in clinical practice. Methods: Herein, the Fe3O4@ZIF-8 core–shell nanoparticles (NPs) platform designed for jaw OM treatment consisted of Fe3O4 as the core and zeolitic imidazolate framework-8 (ZIF-8) as the shell. Results: The core–shell platform not only integrated the pH-responsive degradation capability of ZIF-8 but also retained the superparamagnetism of Fe3O4 NPs. In the acidic, infectious microenvironment, Fe3O4@ZIF-8 NPs underwent continuous degradation, releasing Zn2+, thereby conferring potent antibacterial activity. The specific antibacterial mechanism of the nanoparticles lies in the fact that high concentrations of Zn2+ directly disrupted bacterial cell membranes and inhibited the bacterial heat shock response. This dysregulates bacterial proteostasis, rendering the bacteria more sensitive to external adverse stresses, ultimately leading to bacterial death. With ZIF-8 framework degradation, the encapsulated Fe3O4 NPs were released. Under static magnetic field (SMF) synergy, Fe3O4 NPs collaborated with Zn2+ to promote bone regeneration and repair infected bone defects in jaw OM lesions. Conclusions: As a multifunctional core–shell platform, Fe3O4@ZIF-8 NPs meet the dual clinical needs of antibiosis and osteogenesis, offering a promising translational strategy for jaw OM therapy.
- Open Access
- 9 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 216
Exosomes Derived from BMSCs Treated with CeONPs Ameliorate Radiation-Induced Jaw Bone Injury via miR-21-5p/STAT3 Axis-Mediated Osteogenesis and ROS Scavenging
Background/Objectives: Radiation-induced jaw bone injury is a severe and refractory complication following radiotherapy, and the key to treatment is promoting osteogenic differentiation and alleviating oxidative stress injury in irradiated BMSCs. Cerium oxide nanoparticles (CeONPs) exhibit considerable research potential in various oxidative stress injury-related diseases due to their excellent reactive oxygen species (ROS) scavenging capacity; however, its biosafety risk makes direct application in disease treatment a matter of controversy. Methods: Recent evidence suggests that treating cells with nanoparticles can regulate the content of exosomes, enhancing the regenerative potential of exosomes. Accordingly, this study was designed to explore the therapeutic effects and underlying mechanism of exosomes derived from BMSCs treated with CeONPs (BMSC-Ce-exos) in radiation-induced jaw bone injury. Results: In vitro, 25 μg/mL CeONPs were identified as the optimal treatment concentration; BMSC-Ce-exos significantly promoted the osteogenic differentiation and reduced the ROS levels of irradiated BMSCs. In vivo, BMSC-Ce-exos notably promoted bone formation and decreased the ROS levels in rats with radiation-induced jaw bone injury. miRNA sequencing revealed that BMSC-Ce-exos were highly enriched with miR-21-5p, which promoted the osteogenic differentiation and reduced the ROS levels of irradiated BMSCs through targeting STAT3. Conclusions: Collectively, these results suggest that BMSC-Ce-exos provided a potential therapeutic approach for radiation-induced jaw bone injury.
- 9 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (2) , 216
Open AccessExosomes Derived from BMSCs Treated with CeONPs Ameliorate Radiation-Induced Jaw Bone Injury via miR-21-5p/STAT3 Axis-Mediated Osteogenesis and ROS Scavenging
Background/Objectives: Radiation-induced jaw bone injury is a severe and refractory complication following radiotherapy, and the key to treatment is promoting osteogenic differentiation and alleviating oxidative stress injury in irradiated BMSCs. Cerium oxide nanoparticles (CeONPs) exhibit considerable research potential in various oxidative stress injury-related diseases due to their excellent reactive oxygen species (ROS) scavenging capacity; however, its biosafety risk makes direct application in disease treatment a matter of controversy. Methods: Recent evidence suggests that treating cells with nanoparticles can regulate the content of exosomes, enhancing the regenerative potential of exosomes. Accordingly, this study was designed to explore the therapeutic effects and underlying mechanism of exosomes derived from BMSCs treated with CeONPs (BMSC-Ce-exos) in radiation-induced jaw bone injury. Results: In vitro, 25 μg/mL CeONPs were identified as the optimal treatment concentration; BMSC-Ce-exos significantly promoted the osteogenic differentiation and reduced the ROS levels of irradiated BMSCs. In vivo, BMSC-Ce-exos notably promoted bone formation and decreased the ROS levels in rats with radiation-induced jaw bone injury. miRNA sequencing revealed that BMSC-Ce-exos were highly enriched with miR-21-5p, which promoted the osteogenic differentiation and reduced the ROS levels of irradiated BMSCs through targeting STAT3. Conclusions: Collectively, these results suggest that BMSC-Ce-exos provided a potential therapeutic approach for radiation-induced jaw bone injury.
- Open Access
- 16 May 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (5) , 652
From Mechanism to Therapy: The Role of MSC-EVs in Alleviating Radiation-Induced Injuries
Radiation injury is a severe issue in both nuclear accidents and cancer radiotherapy. Ionizing radiation impairs the regenerative and repair capabilities of tissues and organs, resulting in a scarcity of effective therapeutic approaches to prevent or mitigate such injuries. Mesenchymal stem cells (MSCs) possess favorable biological characteristics and have emerged as ideal candidates for the treatment of radiation injury. However, the use of MSCs as therapeutic agents is associated with uncertainties in therapeutic efficacy, transient effects, and the risk of immune rejection. Recent advances in research have revealed that extracellular vesicles (EVs) derived from mesenchymal stem cells (MSC-EVs) exhibit similar beneficial properties to MSCs and represent a promising cell-free therapy for mitigating radiation injuries. MSC-EVs are enriched with microRNAs (miRNAs), proteins, and lipids, which can modulate immune responses, inflammatory reactions, cell survival, and proliferation in irradiated tissues. This review synthesizes recent studies on the application of MSC-EVs in radiation injury, focusing on the therapeutic effects and mechanisms of MSC-EVs derived from various sources in radiation-induced diseases of different organs. The therapeutic potential of MSC-EVs for radiation injury provides valuable insights for addressing ionizing radiation-induced injuries and offers a reference for future clinical applications.
- 16 May 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (5) , 652
Open AccessFrom Mechanism to Therapy: The Role of MSC-EVs in Alleviating Radiation-Induced Injuries
Radiation injury is a severe issue in both nuclear accidents and cancer radiotherapy. Ionizing radiation impairs the regenerative and repair capabilities of tissues and organs, resulting in a scarcity of effective therapeutic approaches to prevent or mitigate such injuries. Mesenchymal stem cells (MSCs) possess favorable biological characteristics and have emerged as ideal candidates for the treatment of radiation injury. However, the use of MSCs as therapeutic agents is associated with uncertainties in therapeutic efficacy, transient effects, and the risk of immune rejection. Recent advances in research have revealed that extracellular vesicles (EVs) derived from mesenchymal stem cells (MSC-EVs) exhibit similar beneficial properties to MSCs and represent a promising cell-free therapy for mitigating radiation injuries. MSC-EVs are enriched with microRNAs (miRNAs), proteins, and lipids, which can modulate immune responses, inflammatory reactions, cell survival, and proliferation in irradiated tissues. This review synthesizes recent studies on the application of MSC-EVs in radiation injury, focusing on the therapeutic effects and mechanisms of MSC-EVs derived from various sources in radiation-induced diseases of different organs. The therapeutic potential of MSC-EVs for radiation injury provides valuable insights for addressing ionizing radiation-induced injuries and offers a reference for future clinical applications.